

Marianne Abifadel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1266761/publications.pdf>

Version: 2024-02-01

33
papers

6,008
citations

318942

23
h-index

445137

33
g-index

34
all docs

34
docs citations

34
times ranked

7008
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren. <i>Metabolites</i> , 2022, 12, 504.	1.3	1
2	Pathogenic variants in THSD4, encoding the ADAMTS-like 6 protein, predispose to inherited thoracic aortic aneurysm. <i>Genetics in Medicine</i> , 2021, 23, 111-122.	1.1	25
3	Phospholipid transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis is directly correlated with HDL-cholesterol levels and is not associated with cardiovascular risk. <i>Atherosclerosis</i> , 2021, 324, 1-8.	0.4	3
4	Dietary Patterns and Risk Factors of Frailty in Lebanese Older Adults. <i>Nutrients</i> , 2021, 13, 2188.	1.7	6
5	Identification of a Variant in APOB Gene as a Major Cause of Hypobetalipoproteinemia in Lebanese Families. <i>Metabolites</i> , 2021, 11, 564.	1.3	5
6	New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia. <i>Scientific Reports</i> , 2018, 8, 1943.	1.6	25
7	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.4	163
8	Identification of the first Tangier disease patient in Lebanon carrying a new pathogenic variant in ABCA1. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1374-1382.	0.6	6
9	Plasma proproteinâ€convertaseâ€subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 943-953.	2.2	17
10	The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. <i>Pharmacological Reviews</i> , 2017, 69, 33-52.	7.1	90
11	PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies. <i>Current Atherosclerosis Reports</i> , 2017, 19, 49.	2.0	31
12	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 1377-1392.	2.4	23
13	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.2	90
14	Dyslipidaemia in the Middle East: Current status and a call for action. <i>Atherosclerosis</i> , 2016, 252, 182-187.	0.4	37
15	Familial hypercholesterolemia mutations in the Middle Eastern and North African region: A need for a national registry. <i>Journal of Clinical Lipidology</i> , 2015, 9, 187-194.	0.6	44
16	Characterization of Autosomal Dominant Hypercholesterolemia Caused by <i>PCSK9</i> Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. <i>Circulation: Cardiovascular Genetics</i> , 2015, 8, 823-831.	5.1	90
17	Familial hypercholesterolaemia: A global call to arms. <i>Atherosclerosis</i> , 2015, 243, 257-259.	0.4	148
18	PCSK9 polymorphism in a Tunisian cohort: Identification of a new allele, L8, and association of allele L10 with reduced coronary heart disease risk. <i>Molecular and Cellular Probes</i> , 2015, 29, 1-6.	0.9	8

#	ARTICLE	IF	CITATIONS
19	MFAP5 Loss-of-Function Mutations Underscore the Involvement of Matrix Alteration in the Pathogenesis of Familial Thoracic Aortic Aneurysms and Dissections. <i>American Journal of Human Genetics</i> , 2014, 95, 736-743.	2.6	110
20	Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. <i>Current Atherosclerosis Reports</i> , 2014, 16, 439.	2.0	87
21	Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. <i>Atherosclerosis</i> , 2012, 223, 394-400.	0.4	92
22	Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients. <i>Atherosclerosis</i> , 2012, 222, 158-166.	0.4	22
23	TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. <i>Nature Genetics</i> , 2012, 44, 916-921.	9.4	319
24	Molecular analysis and intestinal expression of SAR1 genes and proteins in Anderson's disease (Chylomicron retention disease). <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 1.	1.2	116
25	In Vivo Evidence That Furin from Hepatocytes Inactivates PCSK9. <i>Journal of Biological Chemistry</i> , 2011, 286, 4257-4263.	1.6	132
26	Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. <i>Expert Opinion on Therapeutic Patents</i> , 2010, 20, 1547-1571.	2.4	28
27	Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (<i>PCSK9</i>) gene in cholesterol metabolism and disease. <i>Human Mutation</i> , 2009, 30, 520-529.	1.1	211
28	The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum of <i>LDLR</i> mutations and role of <i>PCSK9</i> as a modifier gene. <i>Human Mutation</i> , 2009, 30, E682-E691.	1.1	82
29	Novel mutations of the <i>PCSK9</i> gene cause variable phenotype of autosomal dominant hypercholesterolemia. <i>Human Mutation</i> , 2005, 26, 497-497.	1.1	169
30	Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations in <i>PCSK9</i> . <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1448-1453.	1.1	171
31	NARC-1/ <i>PCSK9</i> and Its Natural Mutants. <i>Journal of Biological Chemistry</i> , 2004, 279, 48865-48875.	1.6	544
32	Heterozygous <i>TGFBR2</i> mutations in Marfan syndrome. <i>Nature Genetics</i> , 2004, 36, 855-860.	9.4	577
33	Mutations in <i>PCSK9</i> cause autosomal dominant hypercholesterolemia. <i>Nature Genetics</i> , 2003, 34, 154-156.	9.4	2,532